Document Type

Article

Publication Date

1-1-2015

Identifier

PMCID: PMC4471311 DOI: 10.1155/2015/714964

Abstract

CLCF-1 is a cytokine known for B-cell stimulation and for neurotrophic properties. We have identified CLCF-1 as a potential injurious factor in the human renal disease focal segmental glomerulosclerosis (FSGS). We investigated its effects on renal cells and renal function in in vitro and in vivo studies. Methods include measurement of the effect of CLCF-1 on phosphorylation of target molecules of the JAK/STAT pathway, on cytoskeleton and cell morphology in cultured podocytes, on albumin permeability of isolated rat glomeruli, and on tissue phosphorylation and urine albumin after acute or chronic CLCF-1 injection. In addition, cell sorting was performed to determine the presence of cells expressing CLCF-1 in spleen and bone marrow of normal mice and the effect of CLCF-1 infusion on splenic B-cell populations. CLCF-1 increased phosphorylation of STAT3 in multiple cell types, activated podocytes leading to formation of lamellipodia and decrease in basal stress fibers, increased glomerular albumin permeability, and increased STAT3 phosphorylation of peripheral blood cells and renal cortex. CLCF-1 increased urine albumin/creatinine ratio in mice and increased B-cell expression of IgG in mouse spleen. We conclude that CLCF-1 has potentially important systemic effects, alters podocyte function, and may contribute to renal dysfunction and albuminuria.

Journal Title

J Immunol Res

Volume

2015

First Page

714964

Last Page

714964

MeSH Keywords

Actin Cytoskeleton; Animals; B-Lymphocytes; Blood Cells; Bone Marrow Cells; Cytokines; Humans; Interleukin-6; Janus Kinase 2; Kidney; Kidney Cortex; Kidney Glomerulus; Male; Mice; Phosphorylation; Podocytes; Rats; Recombinant Proteins; Spleen

Download

Share

COinS